CLLS Cellectis S.A.

NASDAQ
$1.06

Cellectis S.A. Q3 F2026 Earnings Call Transcript

AI Conference Call Analysis

Sign in or subscribe to read.
Conference Operator
Operator
Thank you for your continued patience. Your meeting will begin shortly. If you do need assistance at any time today, please press star zero and a member of our team will be happy to help you. Thanks again, everyone.
Unknown
Unidentified prerecorded audio
Thank you for watching! . . . © transcript Emily Beynon © transcript Emily Beynon ¶¶ ¶¶
Conference Operator
Operator
Ladies and gentlemen, again, thank you for your continued patience and holding. Again, your meeting will begin shortly, but if you do need assistance at any time today, please press star zero, and a member of our team will be happy to help you.
Unknown
Unidentified prerecorded audio
. . . . Thank you for watching!
Conference Operator
Operator
Please stand by, your meeting is about to begin.
Conference Operator
Operator
Hello and welcome everyone, joining today's Selectis third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star one on your telephone keypad. Please note this call has been recorded and we are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Arthur Stril, Chief Financial Officer and Business Officer. Please go ahead.
Arthur Stril
Chief Financial Officer and Chief Business Officer
Good morning and welcome everyone to Selected's Third Quarter 2026 Business Update and Financial Results Conference Call. Joining me on the call today are Dr. Andre Choulika, our Chief Executive Officer, and Dr. Adrian Kilcoyne, our Chief Medical Officer. Yesterday evening, Selective issued a 6K and press release reporting on financial statements for the nine-month period ended September 30, 2026, and a business update. The report and press release are available on our website at selective.com. As a reminder, Please note that this presentation contains forward-looking statements within the meaning of applicable securities laws, including statements regarding our strategy, development programs, financial condition, and expected cash runways. These forward-looking statements are based on current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. For a discussion of these risks and uncertainties, please refer to our filings with the U.S. Securities and Exchange Commission and our annual financial report prepared in French. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements contained in this presentation. I would now like to turn the call over to Andre.
Andre Choulika
Chief Executive Officer
Thank you, Arthur. Good morning, and thank you everyone for joining us today. Two months ago, we announced the strategic transformation of selectives into an in vivo gene editing company. In September, our team has been fully committed to this new chapter. We're starting with severe dyslipidemia, where the unmet medical need remains high. In severe hypertriglyceridemia, Persistently elevated triglyceride levels can expose patients to serious complications, including acute pancreatitis. While in severe hypercholesterolemia, prolonged exposure to very high LDL cholesterol substantially increases the risk of cardiovascular disease. For many of these patients, treatment can mean daily pills or repeated injections over the long term. without always achieving sufficient lipid control. Our approach is different. A single injection designed to deliver a potential long-lasting effect. This is what HEAL-101 and HEAL-21 are being developed to achieve. Let me start with HEAL-101, our in vivo base editing candidate targeting the APOC3 gene for severe hypertriglyceridemia. at the European Society of Gene and Cell Therapy in October, we presented an extended preclinical data set after a single administration of HEAT-101 edited up to 70% of APOE-C3 genes with activity restricted to the liver and constantly reduced to glyceride by 76% in a disease model. Taken together, these results strengthen our confidence in HEAL 101 as we continue to advance the program throughout the clinic. Adrian will walk you through the details in a moment. The initiation of the investigator-initiated trial in China is on track, with preliminary clinical data expected in second half of 2027. Turning now to the second lead program, HEAL 201 and an in vivo gene editing candidate targeting PCSK9 gene for severe hypercholesterolemia. It is designed to durably silence PCSK9 without altering the DNA sequence. Our preclinical data are encouraging. In vitro, in human epigenetic cell line, our PCSK9 epigenetic modulator achieves high onsite epigenetic editing with a mean above 90%. and no off-site changes in gene or protein expression detected. In vivo, it reduced new plasma PCSK9 levels by more than 90% in the humanized liver mouse model. Building on these results, we are now preparing the next step, which we plan to be phase one with preliminary clinical data expected in the first half of 2028. I'd like to say a word about our legacy cell therapy programs. Stopping the development of plasma cell and eticel was not an easy decision. Behind these programs are patients and families, as well as investigators and site teams who have been part of these programs over the years. We're deeply grateful to all of them. Our priority now is clear, to advance HEAL 101 and HEAL 201 towards the clinic while maintaining the financial discipline required to reach the key milestones ahead. Alongside the strategic focus, our partnership with AstraZeneca, Jereviate, Allogene, and Iovance remain an important source of value for selectives. With that, I hand over to Adrian, our chief medical officer, who will take you through the HEAL-101 data in more detail. Thank you, Andre. Good morning, everyone.
Adrian Kilcoyne
Chief Medical Officer
Let me start with a brief reminder of how HEAL-101 works. HEAL-101 is a tail-based editor designed to make a single C2T conversion in the Apple C3 gene. This creates a stop codon that prevents production of the Apple C3 protein without cutting DNA, are creating a double strand break. The data we presented at ESGCT built on what we first shared in September and addresses four key questions. One, how efficiently yield 101 edits its target. Two, how precisely that editing is. Three, whether it translates into a functional effect. And finally, where that activity occurs. In a human hepatic cell line, Heal 101 achieved a mean Apple C3 editing of approximately 90% while generating minimum indel and no detectable DNA double strand breaks at the target site. Additionally, no detectable editing was observed at the top putative off-target sites, and this editing resulted in a marked reduction in Apple C3 protein secretion. In a normal lipidemic humanized liver-mouse model, a single intravenous dose resulted in a mean ApoC3 editing of approximately 65%, with editing levels reaching up to 70%. This was accompanied by lower circulating ApoC3 levels and lower triglycerides, demonstrating the effect from gene editing to protein reduction and ultimately to the lipid phenotype. Importantly, we observed no significant increase in ALT levels compared with untreated controls. In a hypertriglyceridemic human APOC3 transgenic mouse model, which more closely reflects the disease setting, HEAL-101 reduced APOC3 levels by 67%. This translated into a 76% reduction in triglycerides, consistent with the efficacy we first reported in September. Importantly, editing was detected in the liver with no significant editing detected in the other tissues analyzed. This liver-restricted activity is consistent with the intended profile of our liver-directed LMP delivery approach and is an important consideration as we advance HeLa-101 towards the clinic. Taken together, these preclinical data show a consistent profile, efficient and precise editing, a functional effect on triglycerides and editing activity restricted to the target organ. As Andre mentioned, our goal with HEAL 101 is to develop a single administration therapy with the potential to provide a lasting reduction in triglycerides. The initiation of the investigator-initiated trial in China is on track with preliminary clinical data expected in the second half of 2027. We look forward to sharing more details on the trial as it progresses. With that, I'll turn the call over to Arthur, our Chief Financial Officer and Chief Business Officer for our third quarter financial results.
Arthur Stril
Chief Financial Officer and Chief Business Officer
Thank you, Adrian. I will now walk you through our financial results for the third quarter of 2026. As Andre highlighted, this is a transition quarter. As part of our strategic transformation, The exit of selected plasma cell and SSL clinical programs is proceeding as planned. Enrollment has stopped, site close-out activities are underway, and treated patients will continue to be monitored in accordance with protocol-specified soil lock requirements. Furthermore, the realignment of the company's operating model is ongoing. In connection with this initiative, the company currently expects its global headcount to be reduced by up to 70% from its pre-transition level over the course of 2026 and 2027, subject to the completion of the applicable French Works Council conciliation process and compliance with applicable French and U.S. labor law requirements. Going forward, we expect selective cash spending to be primarily focused on advancing our pipeline, including HEAL 101, HEAL 201, and potential new product candidates, as well as funding one-off restructuring costs. As of September 30, 2026, our cash, cash equivalents, restricted cash, and fixed-term deposits classified as current and non-current financial assets amounted to $149 million, compared to $211 million as of December 31, 2025. The $62 million change was primarily driven by payments to suppliers of $37.9 million, payroll-related payments, Salaries, Bonuses, and Social Charges of $37.5 million, lease liability payments of $7.3 million, repayment of $4.0 million under the PGE loan, and capital expenditures of $1.9 million, partially upset by $21.4 million of cash received from customers, and $5.4 million of interest received from our financial and cash equivalent instruments. Consolidated revenues and other income were $19.9 million for the nine-month period ended September 30, 2026, compared to $67.4 million for the nine-month period ended September 30, 2025. The $47.5 million decrease year-over-year was primarily driven by the level of activities performed under the research plans of the AstraZeneca Joint Research Collaboration Agreement during the period. Consolidated R&D expenses were $108.8 million for the nine-month period ended September 30, 2026, compared to $69.1 million for the nine-month period ended September 30, 2025. The $39.7 million increase was primarily driven by a $34.9 million impact from the strategic transformation announced in September 2026, including a $26.6 million one-off impairment loss, and a number of others. mainly attributable to the higher clinical development costs incurred before the strategic transformation. Consolidated SG&A expenses were $17.5 million for the nine-month period ended September 30, 2026, compared to the $15.0 million for the nine-month period ended September 30, 2025. The $2.5 million increase was primarily driven by a $1.1 million impact of the strategic transformation announced in September 2026, comprising $0.9 million of termination benefits. Exceeding the one-off impact, selling general and administrative expenses increased by $1.4 million, mainly due to higher stock-based compensation expense. Turning to our financial results, the consolidated net gain for the nine-month period ended September 30th, 2026 was $5.2 million, compared to a net financial loss of $25.6 million for the nine-month period ended September 30, 2025. The $30.8 million difference reflects a $10.8 million increase in financial income and a $20.0 million decrease in financial expenses. The $10.8 million increase in financial income was primarily attributable to a $14.3 million increase in non-cash gains recognized from fair value measurements, mainly reflecting a gain from the fair value measurements of the tranche A, B, and C warrants issued to the European Investment Bank, EIB, during the period, compared with a fair value loss in the same period in 2025, partially upset by a $2.7 million decrease in interest income earned on cash, cash equivalents, and financial assets, and a $1.0 million decrease in foreign exchange gains. The $20.0 million decrease in financial expenses was primarily attributable to a $23.7 million decrease in foreign exchange losses, mainly resulting from the appreciation of the U.S. dollar against the euro, a $5.9 million decrease in losses from fair value measurements as the tranche A, B, and C warrants issued to the EID generated a fair value gain over the period, and a $9.7 million increase in other financial expenses may be due to the expected credit loss allowance related to a financial warranty. For details on our consolidated metal loss attributable to shareholders for the nine months ended September 30th, 2026, I invite you to refer to our press release. As Andre mentioned, once our realignment is fully implemented as planned, we will have a cash runway into the second half of 2028. Importantly, This is anticipated to take us beyond the expected first clinical data from HEAL 101 in the second half of 2027 and from HEAL 201 in the first half of 2028. Our priorities are clear. We execute our strategic transformation with financial discipline and advance HEAL 101 and HEAL 201 towards their key clinical milestones. With that, we welcome your questions.
Conference Operator
Operator
Thank you. and if you would like to ask a question, please press star one on your keypad. To leave the queue at any time, press star two. Once again, that is star and one to ask a question. We'll take our first question from Amin Makarim with Jefferies. Please go ahead, your line is open.
Amin Makarim
Analyst, Jefferies
Hi, thank you for taking our questions. A couple of questions from us. For HEAL 101, what level of triglyceride lowering would be enough to move into a global development? Does it need to be closer to that roughly 80% reduction we see from Plozaciran, or would like a 50% to 60% reduction be enough? And then for 201, what LDL-C reduction did you see alongside the greater than 90% PCSK9 suppression. It would be helpful if you can address those two.
Adrian Kilcoyne
Chief Medical Officer
Thanks for the question. This is Adrian. I'll take the first part of that. So our anticipation is that the efficacy we will see will be at least as good as the current treatment. So I think that's our expectation. There is another aspect to it, which I think we like to talk about in that one is the percentage reduction. The other is the proportion of patients hitting targets. And that's incredibly important. We want to really optimize the number of patients hitting under that target of 500 for a number of reasons. One, the risks associated with hypertriglyceridemia are really based on it being over 500. So that is critical. And certainly in the high risk patient population and previous acute pancreatitis, once you get under that 500, your risks essentially are eliminated. So that's important to also consider. We also know that between the 200 and 500, when we look at any outcomes, we're not able to see a real benefit. So two aspects, we want to optimize the number of patients who hit below target, but we have no reason to believe based on our current data package that we would be anything other than at least as good as the current therapies available. And again, with the HEAL 101 program to remind people that this is being run in China, the regulations in China have changed rather dramatically this year. And this is supported by a very robust preclinical package. For the PCSK 9 90% reduction, we haven't gone public on the LDL-C reductions yet. That will be coming in June, of course.
Unknown
Unidentified participant
But we'll certainly follow up with you. Helpful. Thank you.
Conference Operator
Operator
Thank you.
Conference Operator
Operator
We will move next with Jack Allen with Baird. Please go ahead. Your line is open.
Jack Allen
Analyst, Baird
Great. Thanks for the questions and congrats to the team on the progress made over the course of the quarter. Two quick ones from our end. I guess the first I wanted to ask on HEAL 101 again, I just wanted to, I guess, poke the management's brains a little bit here on how they selected APOC3 versus PTL3. I know there are gene editors going after both these targets. I'm just curious what drove you towards APOC3 and what attracted you to that target? And then briefly on 101 and the study startup activities, have you identified the sites you're going to go into in the investigator-led study in China? and then any color you can provide on the dose escalation plans there. Do you expect to start at an efficacious dose and how many doses could you escalate through? Thanks so much.
Adrian Kilcoyne
Chief Medical Officer
Great. Well, I can start on that. And just I think there's three questions in there. You may have to remind me of some of those we're going through, Jack. So the first, why OpoC3 versus AngPTL3? Given that our indication was hypertriglyceridemia, the first thing we did is actually extensive market research to see what is required in the marketplace. Specifically for hypertriglyceridemia, the general feeling based on that extensive market research across cardiologists, endocrinologists, internists was that optimal reduction in triglycerides is important. The general feeling was that APO-C3 in terms of specifically targeting Triglycerides was still superior to NHPT-L3 in that regard. So it seemed to be the right indication, the right target for specifically hypertriglyceridemia. In terms of the sites in China, yes, we have chosen where we're going to be running this in China. We haven't got agreement to make that public with the Chinese in China, but once we have that, we will share them with you. But suffice to say that we're very satisfied that we will be able to recruit at a pace given the access to a huge number of patients. And it is that the PI in the trial would be considered probably the number one treater in this space in China and has done all the other gene therapy related programs in the past. So extensive experience. and they specifically wanted to do this program because they like the technology. They perceive it to be potentially safer based on no nicks in DNA. The third question was dose escalation. That's really important to us. We have, again, in choosing the sites in China, the reason we chose the PI was their desire to, yes, start with a safe dose, but also an incredible desire to start with an effective dose. So they have developed their own modeling specific for these types of treatments that allows them to look at, again, the very strong preclinical package we have and do extensive modeling to allow us to start at essentially a slightly higher starting dose. So we do still anticipate dose escalation. Of course, it is a phase one program. However, we do anticipate the dose at which we start will be effective. Now, it may not achieve the optimal efficacy, but it does lead into what the expectations for data readout are for 2027. So once we start the dose escalation in Q1, that first cohort we anticipate will have a level of efficacy. And we would anticipate then by the end of year, you will start to see the durability of that effect, which is a unique proposition from Selectus. and indeed, if we start recruiting patients in Q1, by the end of the year, we should be starting to see the nine-month type of durability of the effect.
Andre Choulika
Chief Executive Officer
One thing I'd like to add, hi Jack, that's Andre, is APOC3 is a way more effective metabolic intervention under reduction of triglyceride than ANGPTL3, which is Thank you very much. on this target that is very valid. So there is a real unmet medical need on this side of a very drastic lowering because of the metabolic action.
Unknown
Unidentified participant
Great. Thanks so much for all the color.
Conference Operator
Operator
Thank you. Our next question comes from Yanan Xu with Wells Fargo.
Conference Operator
Operator
Please go ahead.
Yanan Xu
Analyst, Wells Fargo
Great. Thanks for taking our questions. On the APOC3 program, Could you potentially compare the APOC3 and triglyceride reduction between your base editing approach with nucleus editing approach? Just wondering whether there could be any potential differences. And then could you also touch on Thank you for the question, Yanan.
Andre Choulika
Chief Executive Officer
This is Andre. Well, the effectiveness of either making base editing versus cutting DNA with a double strand break is like the deepness of is very similar with a slight upside for base editing. The difference essentially is that you need to have like a replication inside the cell, but liver cells replicate quite intensively, and therefore you have a very effective base editing. We decided to go for in vivo gene editing with base editors and epigenetic modifiers because the risk of snapping DNA and having what's called anodomagus enjoining that would induce a mutation in the gene is of high risk of potentially having a very, very low rate, but still a rate of translocation or chromotripsis. or loss of heterozygosity. It means you can lose potentially an arm of the chromosome or potentially having the chromosome recombined somewhere else, et cetera. If you just use the deaminase, this will just switch one base for another and after this, there's replication. So the efficiency is similar, if not slightly better with the base editor, but the risk is so much lower that there is actually The main reason to use a nucleus or a double-stranded break, such as a T-Len, N standing for nucleus, it would be essentially to do either gene insertions or gene replacements or a large portion of deletion. But if you just want to interrupt the gene, you can either interrupt it through methylation the deacetylation or essentially base editing inducing either a mutation in the coding sequence or at splice sites. I don't know if this answers the question.
Yanan Xu
Analyst, Wells Fargo
Yeah, that's helpful. Thanks, Andre. And how about the LNT liver safety?
Unknown
Unidentified participant
Yes, it's definitely a safety approach.
Adrian Kilcoyne
Chief Medical Officer
Yeah, as I say, we do have NHP data. We have mouse data. Suffice to say, the liver toxicity has been very reassuring.
Unknown
Unidentified participant
Great. Thanks for the color.
Conference Operator
Operator
Thank you. Our next question comes from Lucas Chamouet with Barclays.
Conference Operator
Operator
Please go ahead.
Lucas Chamouet
Analyst, Barclays
Hi, thanks for taking the question. Real quick on the data reported in the preclinical poster and here today versus September for HEAL 101. Can you talk about what the difference is in the data set in the disease model there?
Andre Choulika
Chief Executive Officer
Well, yeah, actually, there are two different type of models that have been used. The first one is essentially a model that is a human liver that has been grafted on the Nod mice. And so you have the human gene and like, of course, the mouse gene would not work in this setting. And so you need to really test the compound on a real human gene. And so it has been tested in the liver. The problem is that these mice do not develop SHCG. So they're not sick. The second model that has been used is essentially a model that is a transgenic mice. It's a mice liver, but that has a transgene in multiple copies. I think it's approximately over 50 copies of the human APOCY3 gene. and therefore, as there is a lot of APOC3 that is secreted by the mice, the mice develop an SHGG. Therefore, it allows us to show an effective reduction of triglyceride in these types of models and you can make a clear correlation, and that's what the poster shows, between the reduction of APOC3, which goes back to the first question, like the choice of APOC3 versus NGPTL3, and we see that Even over 50 copies in the single hepatocyte can be very efficiently edited by the tile-based editor and reduce the triglycerides. And there is a clear correlation between the number of edits and also the reduction in like the drop in triglycerides. So that's essentially what has been shown essentially working between like a human liver and really diseased mice.
Lucas Chamouet
Analyst, Barclays
Sorry. Okay. So what I meant was in that disease model, the overexpression model, what's the difference between the data now and the data in September? Because the numbers are different.
Andre Choulika
Chief Executive Officer
Well, essentially the correlation that you can do between the reduction triglycerides, like there was like more points of Thank you.
Conference Operator
Operator
and once again that is star and one on your telephone keypad if you would like to join the queue. We will move next with Sylvan Durkan with Citizens. Please go ahead.
Joshua Wurman
Analyst, Citizens (on behalf of Sylvan Durkan)
Hi, this is Joshua Wurman on for Sylvan. Thanks for taking my question and congrats on the updates here. Maybe just going back to the LNP briefly, is this a delivery system that has been used clinically before either by Selectus or elsewhere? and then how can maybe that help us, you know, be informed on the dose escalation? And then additionally, building off the decision to target maybe ApoC3 over AngPTL3, how are you thinking about the ultimate addressable population for 101? If the POC is robust, where do you think the biology could support expansion beyond SHTG? Thank you.
Unknown
Unidentified participant
First of all, the first question was on the LNP.
Andre Choulika
Chief Executive Officer
Oh, the LNP, yes. Sorry about that. I was thinking about the second question. So yes, the answer is yes. We've been working currently with a biotech company, not a CDMO. We're going to transfer to a CDMO after for working with the LNP, but a biotech company that has been using these LNPs in the clinic for transduction of liver cells, but not with messenger RNA or RNA, not especially messenger, sorry, with RNA. for liver transduction with very good safety profile but very high efficiency. And it's like a next generation type of charged type of lipids that have been put and nicely decorated too that gives a very good transduction level in other type of settings. and the liver with RNA and that are currently in the clinic. Therefore, this is why we choose this and there is a very nice modeling that has been done with animal models such as NHP and mice that we're currently conducting that would allow us to translate this and arrive when we'll start in the clinic with probably the best, most The other thing is
Adrian Kilcoyne
Chief Medical Officer
because it has been used clinically before we have the biotechs in HP data which we've been able to recapitulate which is very helpful but also it allows us to go to a dose level which is which I think is part of your second question is it allows us to think about a potentially higher starting dose as well based on the modeling so it's given us that flexibility which has been helpful. And the second part of the question is the size of the market, I think, HbCl3 versus ApoC3, and where could you go beyond? Well, our belief is an ApoC3 target is very much a hypertriglyceridemia target, but this market is incredibly large. So if we look at the target population that we're looking at, It's about 1.1 million across the US and EU5 or EU4 plus UK. So this is an incredibly large market for an APAC-3 target. Again, we've done a lot of market research to see where would this product fit within that market. And the view is based on the potential durability of response, this would be a best in class product. So we will be launching this into An established market being best in class.
Andre Choulika
Chief Executive Officer
The comparison between angPTL3 and APOC3 is that when you're treating severe hypertriglyceridemia, you want a product that is totally focused on this and you will choose the most efficient one. If you're treating, for example, HDL, so hypercholesterolemia, which is also active for angPTL3, I think you'll probably use PCSK9. So I know that this might cover both indications, but as the reduction, it's like not the highest performer in both, but these are two different types of diseases. And usually it doesn't, like the mix between the two, like the overlap is quite small. So it's better used as a very specialized drug in each indication.
Arthur Stril
Chief Financial Officer and Chief Business Officer
Yeah, and two other important points when you think about peak cells is we talk about addressable market, but you also have to think about pricing. So if, as we are thinking about these to be long-lasting treatments, and if you look at the pricing per year per patient of other therapies in the SHTT space, I think proving durability in years will allow us to extract bigger pricing in terms of the per year cost of current therapies. And then finally, when you think about cost of goods, this is MRNA formulated in LNB, which is extremely cheap. So the gross margin potential of these products is absolutely tremendous. So don't only think about the addressable market in terms of number of patients, but I think these therapies will unlock pricing and cost of good opportunities. Absolutely.
Adrian Kilcoyne
Chief Medical Officer
There's a final thing to add, which was we have looked at the market research in this regard regarding the positioning of an AngPT-L3. And the view was this was more a mixed dyslipidemia product. And that's the number of patients that have overlapping LDL-C with hypotric dyslipidemia is actually relatively small. So they see the AngPTL3 probably preferentially moving into that hypercholesterolemia mixed with sylvanemia space. They believe that APOC3 is superior in terms of triglyceride lowering.
Unknown
Unidentified participant
Great. Thank you.
Conference Operator
Operator
Thank you.
Conference Operator
Operator
And at this time, there are no further questions in queue. I will now turn the meeting back to Andre Choulika for closing comments.
Andre Choulika
Chief Executive Officer
Thank you everyone for attending this quarterly financial statement for Selectis and update for the quarter. As we said, we keep on the same timing as we said in September, so we're really excited about what's going to happen in 27. So keep updated on the company on a regular basis and Selectis will be present at many conferences if you want to follow up on the discussion. In the meantime, we'll continue the execution and I would like to thank you for your time.
Conference Operator
Operator
Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.